BioCryst Pharmaceuticals Inc
BCRX
Company Profile
Business description
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Contact
4505 Emperor Boulevard
Suite 200
DurhamNC27703
USAT: +1 919 859-1302
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
435
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.
stocks
What did Morningstar subscribers buy and sell in April?
How the most traded shares in April stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,870.60 | 46.70 | -0.52% |
| CAC 40 | 7,953.99 | 128.28 | -1.59% |
| DAX 40 | 23,974.48 | 481.78 | -1.97% |
| Dow JONES (US) | 50,063.46 | 370.26 | 0.75% |
| FTSE 100 | 10,180.61 | 192.32 | -1.85% |
| HKSE | 25,962.73 | 426.31 | -1.62% |
| NASDAQ | 26,635.22 | 232.88 | 0.88% |
| Nikkei 225 | 61,409.29 | 1,244.76 | -1.99% |
| NZX 50 Index | 12,965.01 | 60.06 | -0.46% |
| S&P 500 | 7,501.24 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,630.80 | 42.70 | -0.49% |
| SSE Composite Index | 4,135.39 | 42.53 | -1.02% |